Bethany Mancilla

Bethany Mancilla is the Chief Business Officer at Capsida Biotherapeutics, a fully integrated gene therapy company developing next generation AAV engineered therapies. Bethany has over 25 years of biotechnology leadership experience in business development, corporate strategy and financing across small and large biopharmaceutical companies. Bethany began her career commercializing innovations and establishing start-up companies from Baylor College of Medicine. She transitioned into emerging biotechnology companies during the genomics era and held increasing roles of responsibility at Gene Logic, a novel drug target discovery company, spear-heading multiple partnerships with leading pharmaceutical companies including Pfizer, Roche, and Lilly. In 2010 she transitioned to VP Business Development for Micromet the developer of the first FDA approved bi-specific T-cell engaging antibody Blincyto® where she had responsibility for US business development and global alliance management. In her role, she forged the strategic partnership with Amgen that led to the company’s acquisition by Amgen. As a key member of the Amgen external research and development team, she assumed escalating roles and responsibilities becoming the Vice President of Business Development overseeing a global team of business development executives. In her current position at Capsida, she leads the company’s business operations including business development, strategy, corporate communications, and intellectual property management. In 2021 she was responsible for the execution of the AbbVie partnership providing $90M upfront for the advancement of gene therapies for neurodegenerative diseases. Ms. Mancilla received an M.B.A. from the University of Houston and a B.A. from the University of Colorado.